Bank of America Securities analyst Alec Stranahan reiterated a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a ...

CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of 61.74% and 252.50%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock ...

BofA analyst Alec Stranahan raised the firm’s price target on Crispr Therapeutics (CRSP) to $86 from $85 and keeps a Buy rating on the shares.

ZUG, Switzerland and BOSTON - CRISPR Therapeutics (NASDAQ:CRSP) reported a narrower-than-expected loss and revenue that surpassed analyst estimates for the fourth quarter of 2024, sending shares up 0.

CRISPR Therapeutics AG (CRSP) closed at $39.41 in the latest trading session, marking a -0.76% move from the prior day.

We recently published a list of 9 Stocks Jim Cramer Talked About. In this article, we are going to take a look at where ...

Check the time stamp on this data. Updated AI-Generated Signals for Crispr Therapeutics Ag (CRSP) available here: CRSP. Type a few symbols and Take a Trial. The signals for these will appear ...

Investors in CRISPR Therapeutics AG (Symbol: CRSP) saw new options begin trading today, for the March 28th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Vanguard Mid-CAP ETF offers a diversified option to invest in numerous mid-cap companies. Here's what investors should know.